The FDA has started a priority review of BeOne Medicines' BCL2 inhibitor sonrotoclax in relapsed or refractory mantle cell lymphoma (MCL), setting up a decision on US approval next year. Sonrotoclax ...
MAXATAWNY TWP., Pa. - From the perspective of the Rodale Institute, there's good news and not-so-good news coming out of Washington, D.C., as of late. First, the not-so-good. The institute, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback